{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:30:45Z","timestamp":1793881845657,"version":"4.7.0"},"reference-count":82,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Although polycystic ovary syndrome (PCOS) is primarily considered a hyperandrogenic disorder in women characterized by hirsutism, menstrual irregularity, and polycystic ovarian morphology, an endocrinological investigation should be performed to rule out other hyperandrogenic disorders (e.g., virilizing tumors, non-classical congenital adrenal hyperplasia (NCAH), hyperprolactinemia, and Cushing\u2019s syndrome) to make a certain diagnosis. PCOS and androgen excess disorders share clinical features such as findings due to hyperandrogenism, findings of metabolic syndrome, and menstrual abnormalities. The diagnosis of a woman with these symptoms is generally determined based on the patient\u2019s history and rigorous clinical examination. Therefore, distinguishing PCOS from adrenal-originated androgen excess is an indispensable step in diagnosis. In addition to an appropriate medical history and physical examination, the measurement of relevant basal hormone levels and dynamic tests are required. A dexamethasone suppression test is used routinely to make a differential diagnosis between Cushing\u2019s syndrome and PCOS. The most important parameter for differentiating PCOS from NCAH is the measurement of basal and ACTH-stimulated 17-OH progesterone (17-OHP) when required in the early follicular period. It should be kept in mind that rapidly progressive hyperandrogenic manifestations such as hirsutism may be due to an androgen-secreting adrenocortical carcinoma. This review discusses the pathophysiology of androgen excess of both adrenal and ovarian origins; outlines the conditions which lead to androgen excess; and aims to facilitate the differential diagnosis of PCOS from certain adrenal disorders.<\/jats:p>","DOI":"10.3390\/diagnostics12092045","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:03:51Z","timestamp":1661375031000},"page":"2045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Differentiating Polycystic Ovary Syndrome from Adrenal Disorders"],"prefix":"10.3390","volume":"12","author":[{"given":"Mert","family":"Yesiladali","sequence":"first","affiliation":[{"name":"Department of Obstetrics & Gynecology, Yeditepe University Kozyatagi Hospital, Atasehir, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis G. K.","family":"Yazici","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Yeditepe University Kozyatagi Hospital, Atasehir, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut","family":"Attar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Yeditepe University Kozyatagi Hospital, Atasehir, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahrettin","family":"Kelestimur","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Yeditepe University Kosuyolu Hospital, Kadikoy, 34718 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1210\/clinem\/dgab613","article-title":"Health care-related economic burden of polycystic ovary syndrome in the United States: Pregnancy-related and long-term health consequences","volume":"107","author":"Riestenberg","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-14-0253","article-title":"The polycystic ovary syndrome: A position statement from the European Society of Endocrinology","volume":"171","author":"Conway","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum. Reprod."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/13543784.2020.1781815","article-title":"Current and experimental drug therapy for the treatment of polycystic ovarian syndrome","volume":"29","author":"Foreste","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Celik, O., and Yildiz, B.O. (2022). Adrenal and Polycystic Ovary Syndrome, Cambridge University Press.","DOI":"10.1017\/9781108989831.008"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1530\/eje.0.1370670","article-title":"The frequency of late-onset 21-hydroxylase and 11 beta-hydroxylase deficiency in women with polycystic ovary syndrome","volume":"137","author":"Sahin","year":"1997","journal-title":"Eur. J. Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/EJE-12-0938","article-title":"Routine screening for Cushing\u2019s syndrome is not required in patients presenting with hirsutism","volume":"168","author":"Karaca","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum. Reprod."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17446651.2019.1576522","article-title":"Hyperandrogenic origins of polycystic ovary syndrome\u2013implications for pathophysiology and therapy","volume":"14","author":"Abbott","year":"2019","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_10","first-page":"113","article-title":"Williams textbook of endocrinology","volume":"12","author":"Vargatu","year":"2016","journal-title":"Acta Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1210\/jcem-36-3-475","article-title":"Serum androstenedione and testosterone levels during the menstrual cycle","volume":"36","author":"Judd","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0300-595X(86)80021-4","article-title":"1 Adrenal and gonadal androgen secretion in normal females","volume":"15","author":"Longcope","year":"1986","journal-title":"Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1210\/jcem-53-1-58","article-title":"Transport of Steroid Hormones: Binding of 21 Endogenous Steroids to Both Testosterone-Binding Globulin and Corticosteroid-Binding Globulin in Human Plasma","volume":"53","author":"Dunn","year":"1981","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","first-page":"347","article-title":"Idiopathic hirsutism","volume":"21","author":"Azziz","year":"2000","journal-title":"Endocr. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1530\/JOE-14-0296","article-title":"Androgen actions in the ovary: Balance is key","volume":"222","author":"Prizant","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.4239\/wjd.v12.i5.616","article-title":"Role of insulin and insulin resistance in androgen excess disorders","volume":"12","author":"Unluhizarci","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.repbio.2015.12.006","article-title":"Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome","volume":"16","author":"Cadagan","year":"2016","journal-title":"Reprod. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1210\/endo.141.8.7595","article-title":"Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17\u03b1-hydroxylase\/17, 20-lyase (CYP17) genes in porcine theca cells","volume":"141","author":"Zhang","year":"2000","journal-title":"Endocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12020-012-9739-3","article-title":"Increased expression of P450scc and CYP17 in development of endogenous hyperandrogenism in a rat model of PCOS","volume":"43","author":"Li","year":"2013","journal-title":"Endocrine"},{"key":"ref_21","unstructured":"Taylor, H.S., Pal, L., and Sell, E. (2019). Speroff\u2019s Clinical Gynecologic Endocrinology and Infertility, Lippincott Williams & Wilkins."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ecl.2005.01.003","article-title":"Hypothalamic\u2013pituitary\u2013adrenocortical axis regulation","volume":"34","author":"Jacobson","year":"2005","journal-title":"Endocrinol. Metab. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/me.2012-1287","article-title":"Structural insights into aldosterone synthase substrate specificity and targeted inhibition","volume":"27","author":"Strushkevich","year":"2013","journal-title":"Mol. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cen.14710","article-title":"Approach to androgen excess in women: Clinical and biochemical insights","volume":"97","author":"Cussen","year":"2022","journal-title":"Clin. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fphar.2018.00940","article-title":"Intracrine regulation of estrogen and other sex steroid levels in endometrium and non-gynecological tissues; pathology, physiology, and drug discovery","volume":"9","author":"Konings","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_26","first-page":"2248","article-title":"Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome","volume":"82","author":"Taylor","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/humrep\/8.suppl_2.123","article-title":"Hypersecretion of luteinizing hormone and the polycystic ovary syndrome","volume":"8","author":"Balen","year":"1993","journal-title":"Hum. Reprod."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/humrep\/16.7.1359","article-title":"Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility","volume":"16","author":"Laven","year":"2001","journal-title":"Hum. Reprod."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1210\/jc.2010-2200","article-title":"Clinical evidence for predominance of delta-5 steroid production in women with polycystic ovary syndrome","volume":"96","author":"Rosencrantz","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1210\/jc.2004-1860","article-title":"Dysregulation of cytochrome P450 17\u03b1-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome","volume":"90","author":"Wickenheisser","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","first-page":"1318","article-title":"Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries","volume":"86","author":"Jakimiuk","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2265.1993.tb01767.x","article-title":"17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome","volume":"39","year":"1993","journal-title":"Clin. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/humrep\/12.5.910","article-title":"17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: Investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation","volume":"12","author":"Sahin","year":"1997","journal-title":"Hum. Reprod."},{"key":"ref_34","first-page":"1711","article-title":"A new contributing factor to polycystic ovary syndrome: The genetic variant of luteinizing hormone","volume":"84","author":"Tapanainen","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tem.2014.12.004","article-title":"Functional genomics of PCOS: From GWAS to molecular mechanisms","volume":"26","author":"McAllister","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_36","first-page":"2317","article-title":"Adrenal androgen excess in the polycystic ovary syndrome: Sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis","volume":"83","author":"Azziz","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1210\/jc.2008-2583","article-title":"Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome","volume":"94","author":"Puurunen","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2265.1997.8700880.x","article-title":"Frequency of a polymorphism in the regulatory region of the 17\u03b1-hydroxylase-17, 20-lyase (CYP17) gene in hyperandrogenic states","volume":"46","author":"Techatraisak","year":"1997","journal-title":"Clin. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0015-0282(99)00118-1","article-title":"Alternate pathway 17, 20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome","volume":"71","year":"1999","journal-title":"Fertil. Steril."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-4757-3906-0_14","article-title":"Insulin resistance in the polycystic ovary syndrome","volume":"15","author":"Dunaif","year":"1997","journal-title":"Clin. Res. Diabetes Obes."},{"key":"ref_41","first-page":"2001","article-title":"Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system","volume":"83","author":"Nestler","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/me.2004-0178","article-title":"Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome","volume":"19","author":"Wickenheisser","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0889-8529(05)70074-8","article-title":"Insulin action in the normal and polycystic ovary","volume":"28","author":"Franks","year":"1999","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM199608293350902","article-title":"Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome","volume":"335","author":"Nestler","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jcem-68-6-1027","article-title":"Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome","volume":"68","author":"Nestler","year":"1989","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1210\/jcem-64-5-960","article-title":"Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids","volume":"64","author":"Cohen","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/molehr\/gah015","article-title":"Anti-M\u00fcllerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment","volume":"10","author":"Weenen","year":"2004","journal-title":"MHR Basic Sci. Reprod. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1210\/endo.142.11.8486","article-title":"Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary","volume":"142","author":"Durlinger","year":"2001","journal-title":"Endocrinology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.fertnstert.2013.04.019","article-title":"Antim\u00fcllerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells","volume":"100","author":"Chang","year":"2013","journal-title":"Fertil. Steril."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0015-0282(16)54890-0","article-title":"Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: Assessment of the adrenal role in ovarian dysfunction","volume":"57","author":"Cedars","year":"1992","journal-title":"Fertil. Steril."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1210\/jcem-72-1-83","article-title":"A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome","volume":"72","author":"Nestler","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJM199410133311502","article-title":"Identification of virilizing adrenal tumors in hirsute women","volume":"331","author":"Derksen","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/jc.2003-031122","article-title":"Androgen excess in women: Experience with over 1000 consecutive patients","volume":"89","author":"Azziz","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_54","first-page":"810","article-title":"Clinical review 56: Nonclassic adrenal hyperplasia: Current concepts","volume":"78","author":"Azziz","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/humupd\/dmx014","article-title":"Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: An update with a special focus on adolescent and adult women","volume":"23","author":"Carmina","year":"2017","journal-title":"Hum. Reprod. Update"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S0962279900001162","article-title":"Pathogenesis and treatment of hirsutism in late-onset congenital adrenal hyperplasia","volume":"4","author":"Carmina","year":"1995","journal-title":"Reprod. Med. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1210\/jc.2011-0225","article-title":"Approach to the girl with early onset of pubic hair","volume":"96","author":"Oberfield","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/jcem.84.5.5683","article-title":"High incidence of molecular defects of the CYP21 gene in patients with premature adrenarche","volume":"84","author":"Dracopoulou","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1210\/jcem-55-5-817","article-title":"Late-onset steroid 21-hydroxylase deficiency: A variant of classical congenital adrenal hyperplasia","volume":"55","author":"Kohn","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1067\/mob.2000.108020","article-title":"21-Hydroxylase\u2013deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter study","volume":"183","author":"Moran","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1210\/jc.2006-1645","article-title":"Nonclassical 21-hydroxylase deficiency","volume":"91","author":"New","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_62","unstructured":"Loh, V., Krishnan, B., Prentice, M., Panahloo, A., and Seal, L. (2009). Late onset congenital adrenal hyperplasia masquerading as subclinical cushing. Endocrine Abstracts, Bioscientifica."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0015-0282(01)02326-3","article-title":"Differential diagnosis of clinically evident hyperandrogenism: Experience with over 1000 consecutive patients","volume":"76","author":"Sanchez","year":"2001","journal-title":"Fertil. Steril."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2003-43307","article-title":"21-hydroxylase-deficient nonclassic adrenal hyperplasia: The great pretender","volume":"21","author":"Moran","year":"2003","journal-title":"Semin. Reprod. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2362.2011.02550.x","article-title":"Non polycystic ovary syndrome\u2013related endocrine disorders associated with hirsutism","volume":"42","author":"Unluhizarci","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2895","DOI":"10.1210\/clinem\/dgaa369","article-title":"Steroid Screening Tools Differentiating Nonclassical Congenital Adrenal Hyperplasia and Polycystic Ovary Syndrome","volume":"105","author":"Maffazioli","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00105-020-04677-1","article-title":"Hyperandrogenismus, adrenale Dysfunktion und Hirsutismus","volume":"71","author":"Makrantonaki","year":"2020","journal-title":"Hautarzt"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101418","DOI":"10.1016\/j.beem.2020.101418","article-title":"Cushing syndrome: Old and new genes","volume":"34","author":"Tatsi","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1530\/EJE-11-0722","article-title":"Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing\u2019s syndrome","volume":"166","author":"Trementino","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000494904","article-title":"Androgens in Cushing\u2019s Syndrome","volume":"53","author":"Arnaldi","year":"2019","journal-title":"Front. Horm. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing\u2019s syndrome: A consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_73","first-page":"3083","article-title":"Menstrual abnormalities in women with Cushing\u2019s disease are correlated with hypercortisolemia rather than raised circulating androgen levels","volume":"83","author":"Perry","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejogrb.2013.12.038","article-title":"Polycystic ovarian syndrome and Cushing\u2019s syndrome: A persistent diagnostic quandary","volume":"175","author":"Brzana","year":"2014","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing\u2019s syndrome: An Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_77","unstructured":"Gardner, D.G., and Shoback, D.M. (2017). Greenspan\u2019s Basic and Clinical Endocrinology, McGraw-Hill Education."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000494905","article-title":"Hyperandrogenism and Adrenocortical Tumors","volume":"53","year":"2019","journal-title":"Hyperandrogenism Women"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2005-1457","article-title":"Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism","volume":"91","author":"Carmina","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09513590.2017.1391205","article-title":"Ovarian volume and PCOS: A controversial issue","volume":"34","author":"Giampaolino","year":"2018","journal-title":"Gynecol. Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fendo.2019.00388","article-title":"Polycystic ovary syndrome and NC-CAH: Distinct characteristics and common findings. A systematic review","volume":"10","author":"Papadakis","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0031-1299765","article-title":"Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome","volume":"120","year":"2012","journal-title":"Exp. Clin. Endocrinol. Diabetes"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/9\/2045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:14:36Z","timestamp":1760141676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/9\/2045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":82,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["diagnostics12092045"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12092045","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}